FDA relaxes oversight of AI-enabled devices and wearables

FDA Regulation Easement: The Food and Drug Administration (FDA) has announced plans to ease regulation of digital health products, following on from the Trump administration’s deregulatory policies for artificial intelligence (AI).
Silicon Valley Influence: FDA Commissioner Marty Makary emphasized the need for the agency to adapt regulations “at Silicon Valley speed” to accommodate rapid technological advancements.
Clinical Decision Support Software: The FDA will alter its approach to clinical decision support software, particularly AI-enabled tools, allowing many products to enter the market without initial FDA review, provided they meet other established criteria.
Promoting Investment and Innovation: One of the agency’s priorities mentioned is fostering a regulatory environment conducive to investment and innovation in health tech.
Contact Information: Reporters for STAT, including Lizzy Lawrence, Mario Aguilar, and Katie Palmer, provide contact details via Signal for further questions.

You may have missed